12
2026-03
Strategic Cooperation Agreement With Fonow Medicine In Relation To KT-939
Suzhou, 12 March, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Suzhou Kintor Pharmaceuticals, Inc. ( “ Suzhou Kintor ”), a wholly-owned subsidiary of the Company, entered into the strategic cooperation agreement (the “ Cooperation Agreement ”) with Zhejiang Fonow Medicine Co., Ltd. *(浙江孚诺医药股份有限公司 ) (“ Fonow Medicine ”) in relation to jointly development of whitening and freckle-removing functional cosmetics containing the Company’s innovative raw material KT-939 as an adjunct option for reducing and improving skin pigmentation.
22
2026-01
Exclusive Sales Agency Agreement In Relation To Anti-Hair Loss Foam Product
Suzhou, 21 January, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Koshine Hong Kong Limited (the “Koshine Hong Kong”), a wholly-owned subsidiary of the Company, entered into an exclusive sales agency agreement (the “Sales Agency Agreement”) with Beijing Dekai Pharmaceutical Technology Co., Ltd* (北京德開醫藥科技有限公司) (the “Dekai Pharmaceutical”) in relation to the sales agency and market promotion (the “Business Cooperation”) of the Company’s anti-hair loss foam product in the Chinese Mainland market.
09
2025-09
Completion Of Enrollment Of Subjects In Long-Term Human Safety Trial Of KT-939
Suzhou, 9 September, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Company has recently completed the enrollment of 130 subjects for the long-term human safety trial (the “Long-Term Safety Trial”) of KT-939, an in-house developed novel and highly effective tyrosinase inhibitor for inhibiting the melanin production. KT-939 precisely targets tyrosinase and effectively blocks the oxidation process of tyrosine, thereby effectively inhibiting melanin production with antioxidant and anti-inflammatory effects, which demonstrates outstanding advantages in both efficacy and safety for cosmetic applications.
12
2025-08
Phase II Clinical Trial Of GT20029 Gel For The Treatment Of Acne In China Reached Primary Endpoint
Suzhou, 12 August, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Phase II Clinical Trial of its in-house developed androgen receptor (AR) proteolysis targeting chimera (PROTAC) compound GT20029 for the treatment of acne has read out the topline results. Results indicated that the Phase II Clinical Trial has successfully met the primary study endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy, safety and pharmacokinetics.
31
2025-07
Suzhou, 31 July, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the enrollment of 666 patients has been completed for the Phase III Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA. The Pivotal Clinical Trial adopts a phase II/III operational seamless design, and the phase II stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety.
24
2025-07
Suzhou, 24 July, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn